Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : CAVALRY'S SHORT BUSTERS - MAGIC EIGHTBALLS PICKS -- Ignore unavailable to you. Want to Upgrade?

To: Spider Valdez who wrote (1247)	10/23/1998 3:47:00 AM
From: Cavalry	Respond to of 1637

tonto was a member of cartel, know i understand, sticking with my heb spreading around the worldHemispherx Lists on Frankfurt Exchange PR Newswire - October 23, 1998 02:45 NEW YORK, Oct. 23 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB) today announced that the Company's shares will be listed on the Frankfurt Stock Exchange and will trade under the symbol HXB, as of October 23, 1998. The listing on the Frankfurt Stock Exchange has been facilitated by ICF Kursmakler, AG. The authorized broker for pricing is Astrid Hoffman. The Frankfurt listing coincides with the Company's active pursuit of a European Union (EU) filing of its drug Ampligen(R) for treatment of Myalgic Encephalomyelitis (ME), known in the United States as Chronic Fatigue Syndrome (CFS). The Company has recently established an office in Belgium and has agreements with a number of prominent European medical scientists in pursuit of EU approval for ME treatment. Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. SOURCE Hemispherx Biopharma, Inc. /CONTACT: William A. Carter, M.D., CEO and Chairman of Hemispherx Biopharma, 215-988-0080; William J. Jenks, Media, 212-232-2222, or fax, 212-232-3232, or Sharon Will, Investor Relations, 212-572-0762, or fax, 212-572-0764, for Hemispherx Biopharma/